{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:49:57Z","timestamp":1732038597029},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>The prolonged use of drugs such as beta-blockers, acetylsalicylic acid, omeprazole, statins, oral contraceptives and hormone replacement therapy might have some role in melanocytic nevi development and be ultimately linked to melanoma risk. Aims of the study were to evaluate a possible association between the above-mentioned drugs and features such as number and atypia of melanocytic nevi in long-term users. We retrospectively looked at pharmacological, clinical and dermoscopic records of 1321 patients that attended our unit for routine mole check between January 2013 and January 2018. Patients were divided into two groups (low or high melanocytic nevi count), and multivariate analysis was performed with regards to the presence and number of melanocytic nevi and drug assumption. A positive association between the use of oral contraceptives or hormone replacement therapy (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.012) and a high melanocytic nevi count was found through multivariate analysis, after adjusting for sex, age and multiple confounding factors, such as freckles, phototype and a reported history of sun exposure and sunburns. Further prospective studies are necessary to establish whether women using oral contraceptives or on hormone replacement therapy should undergo periodic monitoring of pigmented lesions.<\/jats:p>","DOI":"10.1097\/cej.0000000000000545","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T08:35:52Z","timestamp":1569573352000},"page":"338-341","source":"Crossref","is-referenced-by-count":2,"title":["Drug consumption and melanocytic nevi: correlation between oral contraceptives or hormone replacement therapy and a high melanocytic nevi count"],"prefix":"10.1097","volume":"29","author":[{"given":"Roberta","family":"Colucci","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Buzzoni","sequence":"additional","affiliation":[{"name":"Tuscany Cancer Registry, Clinical Epidemiology Unit, Oncological Network, Prevention and Research Institute ISPRO, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Dragoni","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Traniello Gradassi","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereal Diseases, St. Orsola-Malpighi Hospital, Bologna, Italy; Portions of this research were done at affiliation ()"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Galeone","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Crocetti","sequence":"additional","affiliation":[{"name":"Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Moretti","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ad.2011.02.004","article-title":"Melanocytic nevi, melanoma, and pregnancy[in Spanish].","volume":"102","author":"Borges","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2013.09.001","article-title":"Effect of \u03b2-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.","volume":"88","author":"De Giorgi","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/bjd.12692","article-title":"Indicators for the total number of melanocytic naevi: an adjunct for screening campaigns. Observational study on 292 patients.","volume":"70","author":"Echeverria","year":"2014","journal-title":"Br J Dermatol"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cncr.27817","article-title":"Aspirin is associated with lower melanoma risk among postmenopausal caucasian women: the women\u2019s health initiative.","volume":"119","author":"Gamba","year":"2013","journal-title":"Cancer"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.ejca.2011.04.023","article-title":"Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis.","volume":"47","author":"Gandini","year":"2011","journal-title":"Eur J Cancer"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1006\/bbrc.1994.1387","article-title":"Effects of estrogen and estrogen receptor in normal human melanocytes.","volume":"199","author":"Jee","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1038\/cddis.2010.67","article-title":"Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells.","volume":"1","author":"Marino","year":"2010","journal-title":"Cell Death Dis"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1346-8138.2008.00447.x","article-title":"Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas.","volume":"35","author":"Ohata","year":"2008","journal-title":"J Dermatol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fimmu.2013.00062","article-title":"Statins reduce melanoma development and metastasis through MICA overexpression.","volume":"4","author":"Pich","year":"2013","journal-title":"Front Immunol"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.contraception.2009.03.005","article-title":"Inhibitory effects of progestogens on the estrogen stimulation of melanocytes in vitro.","volume":"80","author":"Wiedemann","year":"2009","journal-title":"Contraception"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:09:40Z","timestamp":1693616980000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000545","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,16]]}}}